Board of Directors

Dr. McCarthy serves as the Executive Chairman of Primera Diagnostics.  He currently is a Venture Partner with Ampersand Ventures and is also a member of the Boards of Directors of Viracor-IBT Laboratories, , Magellan Biosciences, Dynex, and Bako Pathology.  Previously, he served as Chairman, CEO and CTO of Focus Diagnostics; as President of Boehringer Mannheim Diagnostics; and as VP of R&D and VP and General Manager at Becton Dickinson & Company.  Dr. McCarthy has also served on the faculties of the Cornell University School of Medicine, the University of North Carolina School of Medicine, and the Johns Hopkins School of Medicine.  He has directed clinical laboratories at the Memorial Sloan-Kettering Cancer Center and at the North Carolina Memorial Hospital.

Dr. Luderer is chief executive officer and member of the board of directors of Integrated Diagnostics, a systems biology focused diagnostics company that was formed from a research collaboration between ISB and the University of Luxembourg.  Previously, Dr. Luderer served as President, chief executive officer and Director of BioTrove Inc., that was aquired by Life Technologies in Decemeber of 2009.  Previous to BioTrove, Dr. Luderer held the CEO position at the venture-backed Light Sciences Inc.  Also, Dr. Luderer served as President and COO of bioMérieux, Inc., VP of Technology and Business Development for Dianon Systems, and VP of Technology Development and Support at Boehringer Mannheim and; Head of Biomedical Research for Corning.   He is an independent director of Agendia BV and Micronics Inc. and an advisor to Washington University’s Biomedical Engineering program.  Dr. Luderer holds a PhD from Rutgers University and performed post doctoral work at Jefferson Medical College in the field of Immunology

Dr. Lennox invests in the biotechnology and molecular diagnostic sectors. He has served on the boards of eighteen companies including General Surgical Innovations, Inc. (acquired by Tyco International Corp.), GeneOhm Sciences, Inc. (acquired by Becton Dickinson), Protometrix, Inc. (acquired by Invitrogen Corp.), and Applied Molecular Evolution Inc. (acquired by Eli Lilly). He was founding CEO of Protometrix, Inc. as well as of CGI Pharmaceuticals, Inc. Ron currently serves as the Chairman of the Board of OpGen, Inc. and on the boards of BIKAM Pharmaceuticals, Inc. and BioRelix, Inc. Prior to the founding of CHL Medical Partners, Ron was a general partner at Hancock Venture Partners (now HarbourVest Partners) where he invested in sixteen healthcare companies, ten of which had successful IPOs. Ron graduated from the University of Glasgow with a B.Sc. in Molecular Biology, Oxford University where he received a D.Phil. in Cell Biology and the Wharton School of the University of Pennsylvania.

Dr. Miles has more than 25 years of management experience in the biotechnology industry. He was most recently Senior Vice President, Business Development, of the Abingworth portfolio company, Alnylam Pharmaceuticals. Before joining Alnylam, Vincent was at Millennium Pharmaceuticals where he held a number of senior management positions in business development, strategic planning and corporate communications. Formerly he was Director of the technology transfer office at the Dana-Farber Cancer Institute and held senior management positions in business development and research at RiboGene and Pharmacia, having begun his career at Amersham International in R&D. He has a BSc in biochemistry and a PhD in molecular biology from University College London. He is based in the Boston office.

Mr. Norhalim Yunus is the Chief Executive Officer of Malaysian Technology Development Corporation (MTDC) Sdn. Bhd., a venture capital company which is a wholly owned subsidiary of Khazanah Nasional Berhad, the investment holding arm of the Government of Malaysia. MTDC is co-manager of the Malaysian Life Sciences Capital Fund (MLSCF) together with Burrill & Co which invests in life sciences companies globally. Norhalim has been with MTDC since 1993 and prior to joining MTDC he was with the research and advisory arm of Kumpulan Guthrie Berhad, the oil palm conglomerate. He is also a council member of the Malaysian Venture Capital Development Council. Norhalim is a biologist by training.

Prior to joining Interwest, Nina was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a healthcare-focused fund. She began her career conducting health policy and survey research with the Kaiser Family Foundation. Nina is a board member of Alyine Pharmaceuticals, she is an observer on the boards of AkaRx Inc., Devax Inc., Kanisa Pharmaceuticals and MacuSight Inc., Nina also played a primary role in Interwest’s investment in Aspreva Pharmaceuticals. She holds a B.S. in human biology from Stanford University.

Dr. Matthew McManus joined PrimeraDx in August 2010 from his prior position as Head of Cleveland Clinic Laboratories (CCL) and the Chief Operating Officer of the Pathology and Laboratory Medicine Institute.  In his three years in Cleveland, he successfully expanded the Clinic's reference laboratory services and secured funding for construction of a major new laboratory facility.  Prior to leading CCL, he was the Medical Scientist for the Novartis Institutes for Biomedical Research Drug Discovery Incubator, where he helped found the External Fast Follower group. He has also worked at McKinsey & Company, consulting for diagnostics, device and other health care clients, and at Procter & Gamble in sales and marketing. He received his MD and Ph.D. from the University of Pennsylvania School of Medicine, his MBA from Boston College, and his BA from the College of the Holy Cross.